Bathla Group Hires Administrators as Australia Housing Slump Deepens 
Yindjibarndi Appeals Fortescue Mining Compensation Ruling 
Google Expands Gemini Enterprise With AI Tools for Legal Sector 
Meta, U.S. States Discuss Settlement in Teen Addiction Trial 
SK Hynix Shares Fall as Workers Reject Wage Deal 
Tokio Marine Eyes Multibillion-Dollar Suncorp Takeover 
Luxshare Shares Rise as First-Half Profit Jumps 18% 
Salesforce Shares Surge as AI Demand Powers Q2 Earnings Beat 
SEC Probes Banks Over Situational Awareness Hedge Fund Collapse 
U.S. Probes Apex Logistics Over Nvidia AI Chip Shipments to China 
Nvidia Reportedly Eyes $13 Billion Hugging Face Acquisition 
SK Biopharmaceuticals Secures Global Rights to Biohaven Epilepsy Drug Opakalim 
Australia’s Big Four Banks Face Mortgage Slowdown as Valuations Draw Scrutiny 
Woodside Drops $5 Billion Clean Energy Plan as Profit Rises 7% 
Shein Hong Kong IPO to Raise $1.7 Billion at $26.5 Billion Valuation 
BNP Paribas, KB Kookmin Eye $2 Billion Techcombank Stake 
Adidas, Puma Shares Fall as Dick’s Sporting Goods Cuts Outlook 
Add as a preferred source on Google
SHANGHAI, China, April 24, 2018 -- Zai Lab Limited (NASDAQ:ZLAB), a Shanghai-based innovative biopharmaceutical company, today announced that members of the senior management team will participate at two upcoming investor conferences. Details of the presentations are as follows:
J.P. Morgan’s Global China Summit
Panel: Innovative Healthcare Panel
Date: Tuesday, May 8, 2018
Location: Beijing, China
Panel Time: 4:00pm CST
Bank of America Merrill Lynch Healthcare Conference
Date: Thursday, May 17, 2018
Location: Las Vegas, Nevada
Presentation Time: 8:00am PST
Individuals may access a live webcast of the Bank of America Merrill Lynch Healthcare Conference presentation on the Zai Lab website at www.zailaboratory.com under "Events & Presentations" in the "Investors" section. A replay of the webcast will be available on this site for 90 days following the live event.
About Zai Lab
Zai Lab (NASDAQ:ZLAB) is a Shanghai-based innovative biopharmaceutical company focused on bringing transformative medicines for cancer, autoimmune and infectious diseases to patients in China and around the world. The company’s experienced team has secured partnerships with leading global biopharma companies, generating a broad pipeline of innovative drug candidates targeting the fast growing segments of China’s pharmaceutical market and global unmet medical needs. Zai Lab’s vision is to become a fully integrated biopharmaceutical company, discovering, developing, manufacturing and commercializing its partners’ and its own products in order to impact human health worldwide.
Contact:
Zai Lab
Billy Cho
+86 137 6151 2501
[email protected]
Solebury Trout
John Graziano
+1 646 378 2942
[email protected]
